[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2470168T3 - Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi - Google Patents

Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi Download PDF

Info

Publication number
DK2470168T3
DK2470168T3 DK10747777.0T DK10747777T DK2470168T3 DK 2470168 T3 DK2470168 T3 DK 2470168T3 DK 10747777 T DK10747777 T DK 10747777T DK 2470168 T3 DK2470168 T3 DK 2470168T3
Authority
DK
Denmark
Prior art keywords
composition
tocotrienol quinone
cerebral
alpha
subject
Prior art date
Application number
DK10747777.0T
Other languages
English (en)
Inventor
Guy M Miller
Viktoria Kheifets
Original Assignee
Bioelectron Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Tech Corp filed Critical Bioelectron Tech Corp
Application granted granted Critical
Publication of DK2470168T3 publication Critical patent/DK2470168T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

  1. FREMGANGSMÅDER TIL FOREBYGGELSE OG BEHANDLING AF CEREBRAL ISKÆMI PATENTKRAV
    1. Sammensætning til anvendelse i behandling, forebyggelse og/eller bedring af neuronskade, der er forbundet med et cerebralt, iskæmisk event eller hypoxi hos et pattedyreindivid med behov for en sådan behandling, hvor sammensætningen omfatter en effektiv mængde af en tocotrienolquinon, der er udvalgt fra gruppen bestående af alpha-tocotrienolquinon, beta-tocotrienolquinon, gamma-tocotrienolquinon og delta-tocotrienolquinon, eller en blanding deraf, eller en enkelt stereoisomer eller blanding af stereoisomerer deraf; med det forbehold, at individet ikke lider af en mitokondriesygdom.
  2. 2. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen omfatter en effektiv mængde af alpha-tocotrienolquinon eller en hvilken som helst stereoisomer, eller blanding af stereoisomerer, deraf.
  3. 3. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor det cerebrale, iskæmiske event er sekundært til en okklusion af den cerebrale vaskulatur.
  4. 4. Sammensætning ifølge krav 3 til anvendelse som defineret i kravet, hvor okklusionen skyldes en tromboembolus.
  5. 5. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor den cerebrale iskæmi skyldes en spasme i den koronære vaskulatur.
  6. 6. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor det cerebrale, iskæmiske event er sekundært til et ophør af hjertefunktion, en kardiopulmonal bypassprocedure eller et blødningsevent i den cerebrale vaskulatur.
  7. 7. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor tocotrienolquinonsammensætningen omfatter mindst ca. 65 % alpha-tocotrienolquinon.
  8. 8. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen endvidere omfatter en farmaceutisk acceptabel bærer.
  9. 9. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen administreres oralt.
  10. 10. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen administreres parenteralt.
  11. 11. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor sammensætningen omfatter alpha-tocotrienolquinon i et interval fra ca. 1 til ca. 1000 mg pr. kg krops vægt for pattedyreindividet.
  12. 12. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor sammensætningen omfatter alpha-tocotrienolquinon i et interval fra ca. 1 til ca. 50 mg pr. kg kropsvægt for pattedyreindividet.
  13. 13. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor neuronskaden er udvalgt fra neuroncelledød, totalt cerebralt infarktvolumen, cerebral iskæmisk skade, cerebralvævsødem og kognitiv dysfunktion.
  14. 14. Sammensætning til anvendelse i behandling og/eller bedring af et cerebralt, iskæmisk event eller hypoxi hos et pattedyreindivid med behov for en sådan behandling, hvor sammensætningen omfatter en effektiv mængde af en tocotrienolquinon, der er udvalgt fra gruppen bestående af alpha-tocotrienolquinon, beta-tocotrienolquinon, gamma-tocotrienolquinon og delta-tocotrienolquinon, eller en blanding deraf, eller en enkelt stereoisomer eller blanding af stereoisomerer deraf; med det forbehold, at individet ikke lider af en mitokondriesygdom, hvor apopleksi er ét af symptomerne på mitokondriesygdommen.
  15. 15. Sammensætning ifølge krav 14 til anvendelse som defineret i kravet, hvor sammensætningen omfatter en effektiv mængde af alpha-tocotrienolquinon eller en hvilken som helst stereoisomer, eller blanding af stereoisomerer, deraf.
  16. 16. Sammensætning ifølge et hvilket som helst af kravene 1-15 til anvendelse som defineret i kravet, hvor alpha-tocotrienolquinonen eller stereoisomeren, eller blandingen af stereoisomerer, deraf, er den eneste aktive bestanddel, der er til stede i en effektiv mængde i sammensætningen.
DK10747777.0T 2009-08-26 2010-08-24 Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi DK2470168T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
DK2470168T3 true DK2470168T3 (da) 2018-05-07

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10747777.0T DK2470168T3 (da) 2009-08-26 2010-08-24 Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi

Country Status (17)

Country Link
US (3) US20110207828A1 (da)
EP (1) EP2470168B1 (da)
JP (2) JP5785546B2 (da)
CN (1) CN102647981B (da)
AU (1) AU2010286704B2 (da)
BR (1) BR112012004167A2 (da)
CA (1) CA2772294C (da)
DK (1) DK2470168T3 (da)
EA (1) EA028677B1 (da)
ES (1) ES2663709T3 (da)
HU (1) HUE037592T2 (da)
MX (1) MX337990B (da)
NO (1) NO2470168T3 (da)
PL (1) PL2470168T3 (da)
PT (1) PT2470168T (da)
SI (1) SI2470168T1 (da)
WO (1) WO2011025785A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
WO2006130775A2 (en) 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
CA2704473C (en) 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP5902673B2 (ja) * 2010-04-27 2016-04-13 エジソン ファーマシューティカルズ， インコーポレイテッド 眼疾患の処置のためのキノンの製剤
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
HUE047439T2 (hu) * 2012-03-19 2020-04-28 Cidara Therapeutics Inc Echinokandin oszályba tartozó vegyületek adagolási rendjei
EP2892516A1 (en) * 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
RU2015120181A (ru) * 2012-11-13 2017-01-10 Гордаген Фармасьютикалз Пти Лтд Чресслизистая доставка токотриенола
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
KR102626895B1 (ko) 2014-12-16 2024-01-18 피티씨 테라퓨틱스, 인크. (r)-2-하이드록시-2-메틸-4-(2,4,5-트리메틸-3,6-디옥소사이클로헥사-1,4-디에닐)부탄아미드의 다형성 및 무정형 형태
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
JP6905527B2 (ja) 2015-12-17 2021-07-21 ピーティーシー セラピューティクス， インコーポレイテッド 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
EP3651801A4 (en) 2017-07-12 2021-04-07 Cidara Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF MUSHROOM INFECTION
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
EP4038076A1 (en) 2019-10-04 2022-08-10 Stealth BioTherapeutics Inc. Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
JP2022552002A (ja) * 2019-10-17 2022-12-14 ザ・ペン・ステイト・リサーチ・ファウンデイション 出血性脳卒中の治療のための機能的ニューロンの再生
WO2021202986A1 (en) 2020-04-03 2021-10-07 Stealth Biotherapeutics Corp Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
CA3225266A1 (en) 2021-07-08 2023-01-12 Swathi PINNAMANENI Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) * 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
JP2001522880A (ja) 1997-11-17 2001-11-20 リポジェニックス・インコーポレイテッド トコトリエノールを用いて再狭窄を予防する方法
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
CA2430415A1 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
MXPA04001555A (es) * 2001-08-21 2004-10-27 Galileo Pharmaceuticals Inc Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
LT1933821T (lt) * 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
EA019675B1 (ru) * 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EA200900970A1 (ru) * 2007-01-10 2009-12-30 Эдисон Фармасьютикалз, Инк. Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина
CA2704473C (en) * 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EP2242506A4 (en) * 2008-01-07 2011-12-28 Janssen Biotech Inc METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
WO2009111543A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
CA2717734A1 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US20110142834A1 (en) * 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) * 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
WO2010030607A1 (en) * 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) * 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) * 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
BRPI1013377A2 (pt) * 2009-04-28 2017-03-21 Edison Pharmaceuticals Inc formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas
EP2424360A4 (en) * 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
WO2010126911A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
BRPI1011776A2 (pt) * 2009-06-25 2018-03-13 Ampere Life Sciences Inc tratamento de distúrbio pervasivos do desenvolvimento com tocotrienóis ou extratos enriquecidos com trienóis
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
BR112012025558A2 (pt) * 2010-04-06 2016-06-28 Edison Pharmaceuticals Inc tratamento para a ataxia-telangiectasia
JP5902673B2 (ja) * 2010-04-27 2016-04-13 エジソン ファーマシューティカルズ， インコーポレイテッド 眼疾患の処置のためのキノンの製剤
US20120101169A1 (en) * 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20120295985A1 (en) * 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control

Also Published As

Publication number Publication date
PL2470168T3 (pl) 2018-06-29
EA028677B1 (ru) 2017-12-29
HUE037592T2 (hu) 2018-09-28
CA2772294A1 (en) 2011-03-03
NO2470168T3 (da) 2018-06-30
US20180344667A1 (en) 2018-12-06
BR112012004167A2 (pt) 2016-03-29
CN102647981B (zh) 2016-09-28
SI2470168T1 (en) 2018-05-31
JP2015091899A (ja) 2015-05-14
CN102647981A (zh) 2012-08-22
MX2012002374A (es) 2012-04-10
WO2011025785A1 (en) 2011-03-03
ES2663709T3 (es) 2018-04-16
JP5785546B2 (ja) 2015-09-30
AU2010286704A1 (en) 2012-03-22
EP2470168A1 (en) 2012-07-04
PT2470168T (pt) 2018-03-28
JP2013503168A (ja) 2013-01-31
AU2010286704B2 (en) 2016-10-20
MX337990B (es) 2016-03-30
US20110207828A1 (en) 2011-08-25
US20170007553A1 (en) 2017-01-12
CA2772294C (en) 2018-08-21
EP2470168B1 (en) 2018-01-31
EA201200355A1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
DK2470168T3 (da) Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi
US7034054B2 (en) Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US20020132845A1 (en) Compositions and methods for the prevention and treatment of tissue ischemia
CN104379148B (zh) 用于治疗神经障碍的雌激素组分
US20220395460A1 (en) Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
US20100197610A1 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
Sarwer-Foner Recognition and management of drug-induced extrapyramidal reactions and “paradoxical” behavioural reactions in psychiatry
TW202203911A (zh) 細胞老化抑制用組成物及抑制細胞老化的方法
WO2011157059A1 (zh) 异类叶升麻苷或其药学上可接受的盐的用途
KR20180112568A (ko) 계혈등 추출물을 포함하는 암의 예방 및 치료용 조성물
US11185553B2 (en) Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
US20040152764A1 (en) Compositions and methods for the prevention and treatment of cerebral ischemia
EP4338798A1 (en) Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
CN110051671B (zh) 马齿苋酰胺e用于制备治疗缺血性心脏病的药物的用途
KR20060069850A (ko) 비타민 ｃ, 마그네슘, 녹차 추출물을 포함하는 심장혈관계질환을 억제하기 위한 약제 조성물
CN112807296B (zh) 琥珀酸在诊断或治疗自然流产中的应用
Ragan et al. Brain injury associated with chronic alcoholism
KR20200126354A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
CN114886889A (zh) 土木香内酯或其衍生物在制备用于预防或治疗肥胖的药物、保健品或食品中的用途
KR101586016B1 (ko) 데옥시시잔드린의 신규 용도
KR20200042745A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
Smith Effects of Estrogens on Astrocytes Exposed to Stressors
CN111214465A (zh) 维拉帕米的抗衰老用途
Lloyd A quantitative estimation of the effect of rutin on the biological potency of vitamin C